Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-Label Study to Assess the Cardiovascular Side Effects and Efficacy for Reducing Blood Glucose Level in Type II Diabetes Mellitus Patients Being Treated With RAS 130 With or Without Diet and Exercise

NCT00737152 is registered in ClinicalTrials.gov with American Scitech International as lead sponsor.

NCT NCT00737152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00737152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-Label Study to Assess the Cardiovascular Side Effects and Efficacy for Reducing Blood Glucose Level in Type II Diabetes Mellitus Patients Being Treated With RAS 130 With or Without Diet and Exercise
Lead sponsor
American Scitech International
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2011
Completion date
April 30, 2014
Enrollment
460 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

type ii diabetes mellitus